SEARCH:   Advanced

Blood, 13 August 2009, Vol. 114, No. 7, pp. 1429-1436. Prepublished online as a Blood First Edition Paper on June 15, 2009; DOI 10.1182/blood-2009-01-196303. This Article Full Text (PDF) Supplemental Appendix All Versions of this Article: blood-2009-01-196303v1 114/7/1429    most recent e-Letter: Submit a Response Alert me when this article is cited Alert me when e-Letters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Pulsipher, M. A. Articles by Kadota, R. Search for Related Content PubMed PubMed Citation Articles by Pulsipher, M. A. Articles by Kadota, R. Social Bookmarking                         What's this?  Previous Article  |  Next Article  Submitted January 12, 2009 Accepted May 27, 2009 Reduced intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant Consortium (PBMTC) study ONC0313 Michael A. Pulsipher*, Kenneth M. Boucher, Donna Wall, Haydar Frangoul, Michel Duval, Rakesh K. Goyal, Peter J. Shaw, Ann E. Haight, Michael Grimley, Stephan A. Grupp, Morris Kletzel, and Richard Kadota Primary Children's Medical Center, University of Utah School of Medicine, Salt Lake City, UT, United States Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, United States Paediatric Hematology/Oncology, CancerCare Manitoba, Winnepeg, MB, Canada Vanderbilt Children's Hospital, Nashville, TN, United States Hopital Sainte-Justine, Universite of Montreal, Montreal, QC, Canada Children's Hospital of Pittsburgh, Pittsburgh, PA, United States The Children's Hospital at Westmead, NSW, Australia Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, GA, United States Methodist Children's Hospital of South Texas, San Antonio, TX, United States Children's Hospital of Philadelphia, Philadelphia, PA, United States Children's Memorial Medical Center at Chicago, Chicago, IL, United States Rady Children's Hospital San Diego, San Diego, CA, United States * Corresponding author; email: michael.pulsipher{at}hsc.utah.edu. The role of reduced intensity conditioning (RIC) regimens in pediatric cancer treatment is unclear. To define the efficacy of a busulfan/fludarabine/ATG RIC regimen in pediatric patients ineligible for myeloablative transplantation, we completed a trial at 23 institutions in the Pediatric Blood and Marrow Transplant Consortium (PBMTC). Forty seven pediatric patients with hematologic malignancies were enrolled. Sustained engraftment occurred in 98, 89, and 90% and full donor chimerism by day +100 was achieved in 88, 76, and 78% of evaluable related BM/PBSC, unrelated BM/PBSC, and unrelated CB recipients. With a median follow up of 24 months (range 11-53m), 2 year event free survival (EFS), overall survival (OS), transplant related mortality (TRM), and relapse were 40, 45, 11, and 43%, respectively. Univariate analysis revealed a less favorable outcome when patients had undergone previous TBI-containing myeloablative transplantation (2yr OS 23 vs. 63 vs 52%, previous TBI BMT vs. no-TBI BMT vs. no BMT, p=0.02) and when patients not previously treated with TBI had any detectable disease at the time of the RIC procedure (2yr OS 0 vs 63%, detectable vs. non-detectable disease, p=0.01). Favorable outcomes can be achieved with RIC approaches in pediatric patients in remission who are ineligible for myeloablative transplantation. This study is registered at www.clinicaltrials.gov as NCT00795132. CiteULike    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020